Objectives: To determine safety-specific, efficacy-specific and genotypic-specific dose requirements of efavirenz (EFV) in children aged 3 to less than 36 months with HIV infection.
Background
Efavirenz (EFV) is a nonnucleoside reverse transcriptase inhibitor with a relatively narrow therapeutic window and serum concentrations showing high interpatient and intrapatient variability [1, 2] . EFV is recommended by the WHO as first-line treatment for HIV-infected adults and children [3] . Significant pharmacokinetic variability of EFV is related to a single-nucleotide polymorphism in the cytochrome (CYP) P450 2B6 gene (G516T, rs3745274) [4] [5] [6] . The CYP2B6 isoform has been found to be almost exclusively responsible for EFV metabolism to its primary inactive metabolite [7, 8] . The prevalence of CYP2B6 516TT (TT) genotype varies across geographic regions and ethnicities but has been reported in 9-23% of South Africans [9, 10] . Persons having 516TT genotype, also referred to as poor metabolizers, have slower clearance of EFV in comparison with 516GG (GG) or 516GT (GT) genotypes (extensive metabolizers), who exhibit more rapid clearance [8, 11] . Furthermore, liquid formulations have shown erratic absorption and even higher variability [12] . Dose-finding for children aged less than 3 years or weighing less than 10 kg has been particularly challenging as pharmacokinetic studies have shown a greater effect of genotype on EFV metabolism in young children due to high clearance, especially among extensive metabolizers [8] Dutch HIV-infected children with the GG genotype and treated with WHO-approved EFV doses had only a 30-50% probability of achieving a therapeutic trough level of efavirenz [13] . This study aimed to determine the genotype-specific dose requirements of EFV, administered as opened capsules, in HIV-infected children aged 3 to less than 36 months with or without TB coinfection and the 24-week safety and efficacy.
Methods
Study design IMPAACT Protocol P1070 was a prospective, Phase I/II open-label 24-week trial implemented in five tuberculosis (TB)-endemic countries. Children with HIV infection (Cohort I) or HIV/TB coinfection (Cohort II, reported separately), aged 3 months to less than 36 months, initiating antiretroviral therapy were eligible to enroll. Exclusion criteria included prior treatment with or exposure to EFV, infants aged less than 24 months with prior receipt of nevirapine (NVP) or whose mothers received NVP or EFV during gestation or in labor; severe malnutrition, active opportunistic or central nervous system infections that required therapy; or liver enzymes at least Grade 2 using the Division of AIDS (DAIDS) toxicity tables: (http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/daidsaegradingtable.pdf). Participants were stratified into two age groups -3 to less than 24 months and at least 24 to less than 36 months and treated with an antiretroviral regimen consisting of two nucleoside reverse transcriptase inhibitors and weight band-based EFV dosing (Table 1) given as capsules opened into porridge, formula or expressed breast milk. Safety and efficacy were judged by clinical examinations and laboratory testing at study entry, weeks 2 and 4 and then monthly, with HIV RNA level at study entry, weeks 4, 8, 16 and 24. Toxicities were graded using the DAIDS toxicity tables, and an expanded studyspecific table was developed to grade neurotoxicities.
Efavirenz dosing approach
The starting EFV dose was modeled using data from two previous Pediatric AIDS Clinical Trials Group studies of EFV pharmacokinetics in children (P382 and P1021) [8, 14] . In Version 1 of the study, an initial dose of EFV [$1600 mg Â (weight in kg/70) 0.7 rounded for weight band dosing] was chosen for all participants to produce a target area under the curve (AUC) of 35-180 mg Ã h/ml, a systemic exposure similar to that shown to be effective and well tolerated in older children and adults. At the week 2 study visit, a real-time intensive EFV pharmacokinetic assay was performed, and individual participants' doses were adjusted accordingly. Real-time CYP2B6 516 (rs3745274) genotype was also assessed. Extremely high EFV exposures in the first seven TT participants (refer to the 'Results' section) led to a protocol amendment, Version 2, which introduced genotype-guided dosing and incorporated an approximate 75% reduction in EFV dosage for TT participants, [$400 mg Â (weight in kg/70) adjustment; if target AUC was not achieved, participants were discontinued from the study and started on locally prescribed antiretrovirals. The target AUC range (35-180 mg Ã h/ml) corresponds to a drug concentration at 24 h (C24) range of $0.7-4.0 mg/ml. Although both AUC and C24 are highly correlated (r 2 > 0.95), we used AUC to guide dosing as it is less sensitive to deviations in sample collection and prior dosing intervals.
Dose finding guidelines
To establish a dose for each age group, the first eight GG/ GT participants were evaluated on the basis of their week 2 AUC plasma pharmacokinetic results and safety data through week 4. The dose was considered well tolerated for the age group if no participants experienced a Grade 4 life-threatening toxicity or a Grade 4 toxicity accompanying any serious adverse event (SAE) judged to be at least possibly related to EFV. At least six of eight participants were required to achieve a plasma AUC within the target range to deem the dose acceptable.
Determination of efavirenz concentration EFV AUC was determined by noncompartmental methods. DBS samples from intensive pharmacokinetic collections were assayed in real time and used to determine immediate EFV exposure for potential individual dose adjustments. Plasma samples were batched for final pharmacokinetic analysis. The plasma AUC was determined either by direct measurement of the plasma samples or from the DBS samples multiplied by the plasma/DBS ratio (1.30) observed from the first 246 plasma-DBS pairs.
Estimation of efavirenz exposure based on Food and Drug Administration-recommended dosages Pharmacokinetic modeling, using P1070 pharmacokinetic data, was used to estimate the percentage of participants, according to genotype, likely to attain therapeutic EFV target concentrations as per Food and Drug Administration (FDA)-indicated dosages. The predicted EFV exposures (AUC or C24) were calculated and compared with actual exposure from dosing strategies used in P1070. Assuming a linear pharmacokinetic, the observed AUC and C24 from P1070 were multiplied by the ratio of the alternative/actual received doses and were used to generate predicted AUC and C24 for FDA dosing. This was also done to determine differences between Versions 1 and 2 for the TT genotype. The frequency of AUC and C24 in the target ranges of 35-180 mg Ã h/ml and 1-4 mg/ml, respectively, among the three dosing strategies was then compared.
Safety, virology and immunology DBS and plasma samples for resistance mutation genotypes were drawn at entry and at weeks 4 and 24, and batched for correlation with virologic responses. In addition, resistance genotypes were collected if a confirmed virologic endpoint was met (defined as <1 log 10 decrease from entry quantitative HIV RNA and RNA > 400 copies/ml at week 8). A safety endpoint was defined as any treatment-related Grade 3 or 4 toxicity requiring permanent discontinuation of EFV.
Statistical methods
Safety, pharmacokinetic and efficacy analyses included only participants enrolled in Cohort I (non-TB infected) aged 3-36 months. Analyses are presented in aggregate. Several are further stratified by genotype. Descriptive statistics were used to summarize study entry demographic data. Proportions of participants experiencing adverse events deemed at least possibly treatment-related were bounded by 95% exact confidence intervals (CIs). Median and interquartile ranges (IQR) were calculated for AUC, C24 (trough), clearance, maximum concentrations (C max ) and the amount of time the drug was present at maximum concentrations (T max ). The proportion of participants falling within the AUC and C24 targets was estimated to be bounded by 95% exact CIs. Virologic response was analyzed at weeks 4, 8, 16 and 24 using an 'intent-to-treat' (ITT) approach (children who discontinued study treatment for any reason were considered failures). Rates of virologic success and on treatment at the time when the response was evaluated are presented with the corresponding 95% exact CIs. Median log 10 HIV-RNA changes from study entry were calculated in an 'as-treated' analysis such that only participants who remained on study drug and who had evaluable data were included in this analysis.
Ethical review
The protocol, amendments, informed consent forms and relevant study-related documents were reviewed and approved by the ethics committee of each of the participating sites. The study was performed in accordance with Good Clinical Practice and in accordance with country-specific laws and regulations governing clinical studies of investigational products. Written, informed consent was obtained from all participants' legal guardians. ClinicalTrials.gov identifier NCT00802802.
Role of the funding source
The funder representatives were involved in study design, data collection, data analysis, data interpretation and writing of the report. However, the corresponding author had full access to all the data in the study and had final responsibility for the content of the article and the decision to submit for publication.
Results
Forty-seven infants without TB [median age 19 months (13-27 IQR)] were enrolled with 24 weeks median follow-up (18-24 IQR), 28 of whom were aged 3 to less than 24 months. Twenty-two children aged 3-24 months were found to have 516GG/GT and six had 516TT genotypes. Among the 24-36-month age group, 16 had a 516GG/GT genotype and three had 516TT. Baseline characteristics by genotype are summarized in Table 2 .
Pharmacokinetic results
Median EFV concentrations rose significantly 3-8 h after dosing for participants with the 516GG/GT genotype (Fig. 1) . The EFV concentrations in participants with 516TT genotype had EFV concentrations approximately four times greater than those with 516GG/GT genotypes with Version 1 dosing. Although the majority of participants were in the 7.0-13.99-kg weight bands, there was no indication that those near the lower threshold of 7 kg, who received nearly double the mg/kg dose, had higher EFVexposures than those near the upper weight band threshold of 13.99 kg.
Thirty-one of 38 (82%) participants with 516GG/GT genotypes achieved the pharmacokinetic target range with starting dose of $1600 mg Â (weight in kg/70) 0.7 daily (QD) or approximately 40 mg/kg per day. Three of four with AUCs below target met the target with a 50% dose increase but only one of three with AUCs above target reached the target with a 50% dose reduction. Both age groups with 516GG/GT genotypes met the study's dose-finding criteria, so this dose was accepted (Table 3) .
Nine participants had 516TT genotypes. All seven (100%) taking Version 1 EFV dosing ($40 mg/kg QD) had significantly elevated EFV exposures, whereas two of two taking Version 2 dosing ($10 mg/kg QD) achieved the target range. Three of seven (43%) Version 1 516TT participants discontinued the study prematurely because the protocol-directed 50% dose reduction either failed (n ¼ 2) or was predicted to fail (n ¼ 1) to bring their EFV levels within the target range. 
Study discontinuations
Thirty-four of 47 participants (72%) completed 24 weeks of treatment per protocol. Thirteen discontinued early: six (13%) participants were withdrawn for failure to achieve target EFV concentrations despite protocoldefined dose adjustments (five with AUC > 180 mg Ã h/ml and one with AUC < 35 mg Ã h/ml), three (6%) experienced a protocol-defined toxicity (one Grade 4 lipase, deemed on subsequent review, to be probably not related to EFV; one Grade 3 lethargy possibly related to EFV and one Grade 4 absolute neutrophil counts possibly related to EFVTT with AUC > 180 mg Ã h/ml), two were withdrawn by their guardians and two were unable to attend follow-up study visits.
Discussion
The current study has demonstrated that significant pharmacokinetic variability, largely dependent on CYP2B6 G516T genotype, prohibits recommendations for a uniform efavirenz dosing strategy for children aged 3-36 months. Consistent with previous estimates in this setting, over 80% of our participants were extensive metabolizers (516GG/GT genotype) with rapid EFV clearance, thus requiring a high EFV dose of open capsules to achieve therapeutic exposures. However, this high dose was excessive for the 19% who were poor metabolizers (516TT genotype) with EFV approximately four times higher than extensive metabolizers, making genotype-directed dosing particularly important in this age group.
Genotype-directed dosing for efavirenz Moore et al. 1133 Our findings suggest that FDA-approved dosing, which does not consider genotype, is too low for extensive metabolizers and too high for poor metabolizers. Pharmacokinetic modeling anticipates that the FDA EFV dose for children aged less than 3 years would produce subtherapeutic AUCs in 32% of extensive metabolizers, whereas only 11% would be subtherapeutic with P1070 dosing. Young children often present with very high viral loads, and underdosing risks the development of EFV resistance mutations, as illustrated by a recent study of 37 EFV-treated children aged 3 months to 6 years in whom six of 14 (43%) with subtarget EFV levels acquired resistance to EFV during the study [12] . AThai study of 188 school-aged children following FDA-approved weight band dosing correlated EFV concentrations and probability of HIV replication and reported that odds of viral load more than 400 copies/ml increased by 2.1 (odds ratio: 2.1; 95% CI: 1.4-3.0; P ¼ 0.03) for each 0.5 mg/l decrease in EFV C24 [15] . Similarly, Ren et al. [16] reported that six of 15 (40%) South African children aged 3-15 years had subtherapeutic EFV troughs (<1 mg/l), and virologic failure (viral load >200 copies/ml) was observed in three of six (50%) with low levels vs. 2/9 (22%) with EFV troughs more than 1 mg/l.
In a single-site study of 33 children aged 2.1-16.7 (median 8.2) years, Wintergerst et al. reported a trend for a higher incidence of viral load blips in children with subtherapeutic EFV plasma concentrations [17] . Virologic responses of the children in P1070 were encouraging. Seventy-three percent achieved a plasma RNA less than 400 copies/ml, by week 24 (by ITT) and all 32 (100%) participants completing 24 weeks were virologically suppressed. Median viral load decrease was 2.7 log at week 4 and 3.3 log at week 24.
The P1070 EFV dose of $40 mg/kg that proved necessary for extensive metabolizers produced excessive EFV exposures in 100% of the poor metabolizers in protocol Version 1. Reducing the dose by 75% projected that 89% of those with the 516TT genotype would attain the target AUC. In contrast, the FDA-approved EFV dose would generate only 44% in the target range, and 56% would have excessive levels. Wintergest et al. [17] recently expressed concern that the risk of central nervous system (CNS) toxicity (primarily effects on neurocognitive development) in infants may be substantial and should be considered when assessing the risk-benefit ratio of using EFV in HIV-infected infants and children. A trend for higher EFV concentrations in children who experienced CNS-related adverse events was also reported by Van de Wijer et al. [18] . Although there are currently no long-term data available, it is likely that excessive EFV levels would contribute more significantly to CNS side effects than therapeutic levels.
EFV was well tolerated overall, with only two of 47 participants (one GG/one TT) discontinuing due to toxicities possibly related to EFV and no life-threatening or Grade 4 SAEs. We did not see disproportionate CNS toxicity in children with excessive levels, but this may be related to the early dose adjustment based on EFV concentrations and the young age of our participants who may be unable to report subjective complaints.
Although CYP2B6 516 is the most frequently encountered polymorphism influencing EFV metabolism, the effects of other minor frequency mutant alleles remain unclear. The only three extensive metabolizers with AUCs over the target range had 516GT genotypes, two of whom had EFV AUCs more than 400 mg Ã h/ml. It is possible that the assumed 'functional' 516 G allele in these participants possesses a less prevalent, alternative CYP 2B6 mutation associated with reduced activity such as CYP2B6 T983C. This may explain the EFV metabolism in these two participants, mimicking the CYP2B6 516TT phenotype group.
Fillekes et al. [19] reported significant interparticipant variability in 41 3-12-year-old HIV-infected Ugandan children with 17% below therapeutic concentrations and 29% with very high EFV levels. A genotype-directed dosing strategy is likely to minimize excessive exposures yet yield adequate concentrations to ensure viral suppression and avoid possible contributions of ongoing viremia to neurocognitive effects. Although the routine use of genotypic screening remains a challenge in resource-limited settings, HLA-B Ã 5701 screening has been used routinely in mid-income and high-income settings to determine appropriateness of using abacavir for many years. These tests can now be processed within Africa, although genotyping costs are relatively high (approximately $60 per polymorphism, personal communication). An increase in demand and subsequent economies of scale will likely result in a significant decrease in cost, making tests more available to resourcelimited populations. Given the scarcity of antiretroviral drugs suitable for the treatment of infants and young children, and the need for formulations that can be used concomitantly with anti-TB treatment, the use of genotypic testing should be required in children aged under 3 years to ensure that optimal drug levels are achieved. Our study demonstrated that this approach achieved excellent target exposures with favorable safety and virologic outcomes, paving the way for the use of a simple dosing algorithm and suggests that this one-time investment is likely to prove cost-effective over time.
Conclusion
EFV remains an important treatment option in resourcelimited settings with high TB coinfection. Significant interparticipant pharmacokinetic variations, largely dependent on CYP2B6 G516T genotype, challenge the use of uniform EFV dosages for children aged less than 3 years. CYP2B6 genotype-directed EFV dosing can mitigate this challenge by improving therapeutic EFV exposures in children with the more common 516GG and 516GT genotypes and avoiding excessive drug levels in those with 516TT genotypes. The increased proportion of 516TT genotypes in many resource-limited settings makes this approach particularly important.
